![Henk Johan Streefkerk](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Perfil
Henk Johan Streefkerk is currently the Chief Executive Officer & Medical Director at Amarna Therapeutics BV and the Chief Medical Officer at CellProthera SAS.
Cargos activos de Henk Johan Streefkerk
Empresas | Cargo | Inicio |
---|---|---|
CellProthera SAS
![]() CellProthera SAS Medical/Nursing ServicesHealth Services CellProthera SAS operates as a holding company with interests in medical studies on heart diseases. The firm focuses on the development of a stem cell therapy for the regeneration of myocardial tissue allowing the prevention of chronic heart failure following acute myocardial infarct by injecting a cell graft containing antilogous adult stem cells sampled directly from the patient. The company was founded by Philippe H?non in April 2008 and is headquartered in Mulhouse, France. | Director Técnico/Científico/I+D | - |
Amarna Therapeutics BV
![]() Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Director Ejecutivo | 07/06/2023 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
CellProthera SAS
![]() CellProthera SAS Medical/Nursing ServicesHealth Services CellProthera SAS operates as a holding company with interests in medical studies on heart diseases. The firm focuses on the development of a stem cell therapy for the regeneration of myocardial tissue allowing the prevention of chronic heart failure following acute myocardial infarct by injecting a cell graft containing antilogous adult stem cells sampled directly from the patient. The company was founded by Philippe H?non in April 2008 and is headquartered in Mulhouse, France. | Health Services |
Amarna Therapeutics BV
![]() Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Health Services |
- Bolsa de valores
- Insiders
- Henk Johan Streefkerk